Pharma IP Benchmarking: The Complete Playbook for Protecting Pipeline Value Before a Competitor Does
Why IP Benchmarking Is a Revenue Function, Not a Legal One A composition of matter patent on a new drug […]
Unveiling the Secrets Behind Big Pharma’s Patent Thickets
Section 1: The Broken Bargain: How a 20-Year Monopoly Became a 40-Year Rent The patent system’s foundational premise is blunt:
Unveiling the Secrets Behind Big Pharma’s Patent Thickets Read Post »
Patent Prosecution Highway for Drug Patents: The Complete Strategic Playbook
1. Why Prosecution Speed Is a Balance Sheet Issue The 20-year patent term granted under 35 U.S.C. Section 154 is
Patent Prosecution Highway for Drug Patents: The Complete Strategic Playbook Read Post »
Patent Cliff Playbook: Out-License Mature Drug Assets Before LOE Destroys Your P&L
Who this is for: Business development leads managing loss-of-exclusivity (LOE) timelines, IP counsel evaluating secondary patent thickets, portfolio managers modeling
Patent Cliff Playbook: Out-License Mature Drug Assets Before LOE Destroys Your P&L Read Post »
Biosimilar First-Mover Advantage: What the Adalimumab Market Actually Taught Us
The biosimilar first-mover question has a clean theoretical answer and a messy empirical one. Theory says: get to market first,
Biosimilar First-Mover Advantage: What the Adalimumab Market Actually Taught Us Read Post »
How Technology Is Redrawing the Map for Generic Drug Development: AI/ML, Continuous Manufacturing, IP Valuation, and the Competitive Dynamics Shaping the ANDA Landscape Through 2030
Executive Summary Generic pharmaceutical companies face a structural cost squeeze that has worsened since 2016. Teva, Mylan, and Sun Pharma
The Open Pharma Revolution: A Strategic Deconstruction of Collaborative Drug Discovery Business Models
A deep-dive pillar page for pharma/biotech IP teams, R&D leads, and institutional investors. Part 1: The R&D Productivity Crisis —
The $300 Billion Patent Cliff Playbook: Formulary Management, Generic Entry Timing, and IP Strategy for Payers and Analysts
Why Formulary Management Is Now an IP Discipline The pharmaceutical formulary started its modern life as an administrative cost control
America Pays 3x More for the Same Drug: Patent Thickets, PBM Rebate Walls, and the IRA’s Real Impact on Pharma Strategy
The 80/80 Paradox: What the Numbers Actually Say The U.S. pharmaceutical market runs on a structural contradiction that no other
